VEGFA and lung carcinoma: In clinical trials, bevacizumab, a humanised antibody against VEGF, has shown considerable promise and improved survival in patients with colorectal, breast, or lung cancer when used in combination with chemotherapy (Hurwitz et al, 2004; Miller et al, 2005; Sandler et al, 2006).